Jump to content
Invision Community
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
META-99 SEARCH ENGINE             CONTACT US

Stella Wilson

Members
  • Content Count

    19
  • Joined

  • Last visited

Community Reputation

0 Neutral
  1. The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon. The USD 4 billion (by 2030) financial opportunity within the Microbiome Therapeutics (Tx) Market And Diagnostics (Dx) Markets, has been analyzed across the following segments: Type of Therapy (Tx) · Prescription Drug · Prebiotics Type of Molecule (Tx) · Small Molecules · Biologics Target Indication (Tx+Dx) · Acne Vulgaris · Atopic Dermatitis · Clostridium difficile Infection · Colorectal Cancer · Crohn’s Disease · Diabetes · Irritable Bowel Syndrome · Lactose Intolerance · Lung Cancer · Nonalcoholic steatohepatitis (NASH) · Obesity · Ulcerative colitis Therapeutic Area (Tx+Dx) · Autoimmune Disorders · Dental Disorders · Digestive and Gastrointestinal Disorders · Dermatological Disorders · Infectious Disease · Metabolic Disorders · Oncology · Others Key Geographical Regions (Tx+Dx) · North America · Europe · Asia-Pacific and Rest of the World The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain: Key Players: · 4D Pharma · Armata Pharmaceuticals · Evelo Biosciences · Rebiotix (Acquired by Ferring Pharmaceuticals) · Seres Therapeutics · Vedanta Biosciences Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Microbiome Therapeutics: Market Landscape 5. Company and Drug Profiles 6. Microbiome Diagnostics: Market Landscape 7. Fecal Microbiota Therapy (FMT) 8. Attractiveness Competitiveness (AC) Matrix 9. Microbiome Related Initiatives of Big Pharmaceutical Players 10. Start-up Health Indexing 11. Key Therapeutics Areas 12. Funding and Investment Analysis 13. Contract Services for Microbiome Therapeutics 14. Big Data and Microbiome Therapeutics 15. Microbiome Therapeutics: Market Forecast and Opportunity Analysis 16. Microbiome Diagnostics: Market Forecast and Opportunity Analysis 17. Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis 18. Case Study: Microbiome-based Products in Other Industries 19. Concluding Remarks 20. Executive Insights 21. Appendix I: Tabulated Data 22. Appendix II: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  2. Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers. The USD 1.7 billion financial opportunity (by 2030) within the Ophthalmic Drugs Contract Manufacturing Market has been analyzed across the following segments: Type of product · Ophthalmic API · Ophthalmic drug FDF Type of FDF manufactured · Solid · Semi-solid · Liquid / suspension Type of primary packaging · Ampoule / vial · Glass / plastic bottle · Ointment tube · Blister packing · Other forms Scale of manufacturing · Clinical · Commercial Company size · Small · Mid-sized · Large · Very large Target disease indication · Age-related macular degeneration · Dry eye · Glaucoma · Other disease segments Key geographical regions · North America (US, Canada and Mexico) · Europe (UK, Germany, France, Spain, Italy and rest of Europe) · Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific) · Rest of the world The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain: · Akorn · Akums · Bal Pharma · Catalent · Cayman Chemical · Entod Pharmaceuticals · Farmigea · Glenmark Pharmaceuticals · Indiana Ophthalmics · Lomapharm · Medichem · Pillar5 Pharma · Recipharm · Salvat · Sterling Pharmaceutical Services · Sunways India Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Company Competitiveness Analysis 6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles 7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles 8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles 9. Clinical Trial Analysis 10. Capacity Analysis 11. Demand Analysis 12. Market Forecast 13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies 14. SWOT Analysis 15. Survey Analysis 16. Executive Insights 17. Future Growth Opportunities 18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers 19. Appendix 2: Tabulated Data 20. Appendix 3: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  3. Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers. The USD 1.7 billion financial opportunity (by 2030) within the Ophthalmic Drugs Contract Manufacturing Market has been analyzed across the following segments: Type of product · Ophthalmic API · Ophthalmic drug FDF Type of FDF manufactured · Solid · Semi-solid · Liquid / suspension Type of primary packaging · Ampoule / vial · Glass / plastic bottle · Ointment tube · Blister packing · Other forms Scale of manufacturing · Clinical · Commercial Company size · Small · Mid-sized · Large · Very large Target disease indication · Age-related macular degeneration · Dry eye · Glaucoma · Other disease segments Key geographical regions · North America (US, Canada and Mexico) · Europe (UK, Germany, France, Spain, Italy and rest of Europe) · Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific) · Rest of the world The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain: · Akorn · Akums · Bal Pharma · Catalent · Cayman Chemical · Entod Pharmaceuticals · Farmigea · Glenmark Pharmaceuticals · Indiana Ophthalmics · Lomapharm · Medichem · Pillar5 Pharma · Recipharm · Salvat · Sterling Pharmaceutical Services · Sunways India Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Company Competitiveness Analysis 6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles 7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles 8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles 9. Clinical Trial Analysis 10. Capacity Analysis 11. Demand Analysis 12. Market Forecast 13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies 14. SWOT Analysis 15. Survey Analysis 16. Executive Insights 17. Future Growth Opportunities 18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers 19. Appendix 2: Tabulated Data 20. Appendix 3: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  4. Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights · More than 80 companies currently claim to offer manufacturing related services, at different scales of operations, for a variety of oligonucleotide-based products · A wide range of services related to the synthesis, modification and purification of oligonucleotides, are currently offered within a fragmented service provider landscape that is mostly concentrated in the developed geographies · In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; the US and some European nations have emerged as current hubs for oligonucleotide production · Players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and thereby, achieve an edge over competing firms · Service providers are actively investing in expansion projects to upgrade existing capabilities and capacity; several partnerships, mostly focused on offering manufacturing and supply services, have been forged · Over the past few years, more than 270 trials of oligonucleotide-based interventions, across various phases of development and to treat a diverse range of diseases, have been registered across different centers worldwide · Most of the global, annual oligonucleotide manufacturing capacity belongs to established service providers, accounting for over 80% of available capacity across various geographies · The demand for manufacturing of oligonucleotide-based products is expected to increase in the coming years; we believe that the stakeholders may have to expand their respective capacities to ensure consistent supply · We expect oligonucleotide-based drug developers to continue to outsource their manufacturing operations in the short to mid-term; service-based revenues are estimated to grow at an annualized rate of more than 10% · In the long-term, the projected opportunity is anticipated to be well distributed across various therapeutic areas, scales of operation and across companies of different sizes Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Context and Background 3.2. Overview of Oligonucleotide-based Products 3.3. Types of Oligonucleotides 3.3.1. Antisense Oligonucleotides 3.3.2. Aptamers 3.3.3. miRNA 3.3.4. shRNA 3.3.5. siRNA 3.3.6. Other Oligonucleotides 3.4. Custom Synthesis of Oligonucleotides 3.4.1. Process Development and Characterization 3.4.2. Analytical Method Development 3.4.3. Method Validation and Testing 3.4.4. Quality Control and Quality Assurance 3.4.5. Challenges Associated with Custom Synthesis of Oligonucleotides 3.5. Chemical Modification of Oligonucleotides 3.5.1. Backbone Modification 3.5.2. Sugar Ring Modification 3.6. Purification of Oligonucleotides 3.6.1. Desalting 3.6.2. Cartridge Purification 3.6.3. Polyacrylamide Gel Electrophoresis (PAGE) 3.6.4. High Performance Liquid Chromatography (HPLC) 3.7. Outsourcing Oligonucleotide Manufacturing 3.7.1. Need for Outsourcing 3.7.2. Commonly Outsourced Operations 3.7.3. Advantages of Outsourcing Manufacturing Operations 3.7.4. Guidelines for Selecting a Service Provider 3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing 3.9. Recent Developments and Upcoming Trends 4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS) 4.1. Chapter Overview 4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Scale of Operation 4.2.4. Analysis by Geographical Location 4.2.5. Analysis by Location of Manufacturing Facilities 4.2.6. Analysis by Regulatory Accreditations / Certifications 4.2.7. Analysis by Type of Oligonucleotide Manufactured 4.2.8. Analysis by Type of Offering 4.2.9. Analysis by Type of Manufacturing Service(s) Offered 4.2.10. Analysis by Type of Modification(s) Offered 4.2.11. Analysis by Type of Purification Method(s) Used 4.2.12. Analysis by Compliance to cGMP Standards 5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS) 5.1. Chapter Overview 5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape 5.2.1. Analysis by Year of Establishment 5.2.2. Analysis by Company Size 5.2.3. Analysis by Scale of Operation 5.2.4. Analysis by Geographical Location 5.2.5. Analysis by Location of Manufacturing Facilities 5.2.6. Analysis by Regulatory Accreditations / Certifications 5.2.7. Analysis by Type of Oligonucleotide Manufactured 5.2.8. Analysis by Type of Offering 5.2.9. Analysis by Type of Manufacturing Service(s) Offered 5.2.10. Analysis by Type of Modification(s) Offered 5.2.11. Analysis by Type of Purification Method(s) Used 5.2.12. Analysis by Compliance to cGMP Standards 6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS) 6.1. Chapter Overview 6.2. Key Assumptions and Methodology 6.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications 6.3.1. Oligonucleotide Manufacturers in North America 6.3.2. Oligonucleotide Manufacturers in Europe 6.3.3. Oligonucleotide Manufacturers in Asia-Pacific 7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS) 7.1. Chapter Overview 7.2. Key Assumptions and Methodology 7.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Therapeutic Applications 7.3.1. Oligonucleotide Manufacturers in North America 7.3.2. Oligonucleotide Manufacturers in Europe 7.3.3. Oligonucleotide Manufacturers in Asia-Pacific 8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS) 8.1. Chapter Overview 8.2. Ajinomoto Bio-Pharma Services 8.2.1. Company Overview 8.2.2. Service Portfolio 8.2.3. Manufacturing Facilities and Capabilities 8.2.4. Recent Developments and Future Outlook 8.3. Integrated DNA Technologies 8.3.1. Company Overview 8.3.2. Service Portfolio 8.3.3. Manufacturing Facilities and Capabilities 8.3.4. Recent Developments and Future Outlook 8.4. Kaneka Eurogentec 8.4.1. Company Overview 8.4.2. Service Portfolio 8.4.3. Manufacturing Facilities and Capabilities 8.4.4. Recent Developments and Future Outlook 8.5. LGC Biosearch Technologies 8.5.1. Company Overview 8.5.2. Service Portfolio 8.5.3. Manufacturing Facilities and Capabilities 8.5.4. Recent Developments and Future Outlook 8.6. Microsynth 8.6.1. Company Overview 8.6.2. Service Portfolio 8.6.3. Manufacturing Facilities and Capabilities 8.6.4. Recent Developments and Future Outlook 8.7. Sigma Aldrich 8.7.1. Company Overview 8.7.2. Financial Information 8.7.3. Service Portfolio 8.7.4. Manufacturing Facilities and Capabilities 8.7.5. Recent Developments and Future Outlook 8.8. Thermo Fisher Scientific 8.8.1. Company Overview 8.8.2. Financial Information 8.8.3. Service Portfolio 8.8.4. Manufacturing Facilities and Capabilities 8.8.5. Recent Developments and Future Outlook 9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS) 9.1. Chapter Overview 9.2. Agilent Technologies 9.2.1. Company Overview 9.2.2. Financial Information 9.2.3. Service Portfolio 9.2.4. Manufacturing Facilities and Capabilities 9.2.5. Recent Developments and Future Outlook 9.3. BioSpring 9.3.1. Company Overview 9.3.2. Service Portfolio 9.3.3. Manufacturing Facilities and Capabilities 9.3.4. Recent Developments and Future Outlook 9.4. CordenPharma 9.4.1. Company Overview 9.4.2. Service Portfolio 9.4.3. Manufacturing Facilities and Capabilities 9.4.4. Recent Developments and Future Outlook 9.5. Nitto Denko Avecia 9.5.1. Company Overview 9.5.2. Service Portfolio 9.5.3. Manufacturing Facilities and Capabilities 9.5.4. Recent Developments and Future Outlook 9.6. TriLink Biotechnologies 9.6.1. Company Overview 9.6.2. Service Portfolio 9.6.3. Manufacturing Facilities and Capabilities 9.6.4. Recent Developments and Future Outlook 10.PARTNERSHIPS AND COLLABORATIONS 10.1. Chapter Overview 10.2. Partnership Models 10.3. Oligonucleotide Manufacturers: Recent Partnerships and Collaborations 10.3.1. Analysis by Year of Partnership 10.3.2. Analysis by Type of Partnership 10.3.3. Analysis by Type of Partner 10.3.4. Most Active Players: Analysis by Number of Partnerships 10.3.5. Geographical Analysis 10.3.5.1. Most Active Players: Geographical Distribution by Number of Partnerships 10.3.5.2. Intercontinental and Intracontinental Agreements 11.RECENT EXPANSIONS 11.1. Chapter Overview 11.2. Oligonucleotide Manufacturers: Recent Expansions 11.2.1. Analysis by Year of Expansion 11.2.2. Analysis by Type of Expansion 11.2.3. Analysis by Application 11.2.4. Analysis by Location of Facility 11.2.5. Analysis by Expanded Facility Area 11.2.6. Analysis by Expanded Scale of Operation 11.3.7. Most Active Players: Analysis by Number of Expansions 11.3.8. Geographical Analysis 11.3.8.1. Continent-wise Distribution 11.3.8.2. Country-wise Distribution 12.CLINICAL TRIAL ANALYSIS 12.1. Chapter Overview 12.2. Scope and Methodology 12.3. Clinical Trial Analysis: Oligonucleotide-based Drug Products 12.3.1. Analysis by Trial Registration Year 12.3.2. Analysis by Phase of Development 12.3.3. Analysis by Type of Oligonucleotide 12.3.4. Analysis by Type of Oligonucleotide and Phase of Development 12.3.5. Analysis by Trial Recruitment Status 12.3.6. Analysis by Trial Focus Area 12.3.7. Analysis by Target Therapeutic Area 12.3.8. Geographical Analysis by Number of Clinical Trials 12.3.9. Geographical Analysis by Enrolled Patient Population 12.3.10. Analysis by Type of Sponsor / Collaborator 12.3.11. Most Active Players: Analysis by Number of Registered Trials 13.CAPACITY ANALYSIS 13.1. Chapter Overview 13.2. Key Assumptions and Methodology 13.3. Oligonucleotide Manufacturers: Global, Annual Capacity 13.3.1. Analysis by Size of Manufacturer 13.3.2. Analysis by Scale of Operation 13.3.3. Analysis by Location of Manufacturing Facility 14.DEMAND ANALYSIS 14.1. Chapter Overview 14.2. Key Assumptions and Methodology 14.3. Global Demand for Oligonucleotide Manufacturing 14.3.1. Global Commercial Demand for Oligonucleotide Manufacturing 14.3.1.1. Analysis by Type of Oligonucleotide 14.3.1.2. Analysis by Target Therapeutic Area 14.3.1.3. Analysis by Geography 14.3.2. Global Clinical Demand for Oligonucleotide Manufacturing 14.3.2.1. Analysis by Type of Oligonucleotide 14.3.2.2. Analysis by Phase of Development 14.3.2.3. Analysis by Target Therapeutic Area 14.3.2.4. Analysis by Geography 14.4. Demand and Supply Analysis 14.4.1. Demand and Supply Analysis (Scenario 1) 14.4.2. Demand and Supply Analysis (Scenario 2) 14.4.3. Demand and Supply Analysis (Scenario 3) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  5. Roots Analysis has done a detailed study on Neoantigen Targeted Therapies, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights · Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration · Several molecules are in early stages of clinical development; based on delivery strategies, variety of vaccines and immunotherapies have been established for targeting personalized and shared antigens · Over the years, more than 6,000 patents related to neoantigens and affiliated therapies have been granted / filed; this is indicative of the heightened pace of research in this field · Both industry and academic players are contributing to the innovation, which is evident across published scientific literature focused on multiple targeted therapies for a myriad of cancer indications · Several investors, having realized the untapped opportunity within this emerging segment of cancer immunotherapy, have invested over USD 7 billion across 150 instances in the period between 2014 and 2019 · The increasing traction in this field is also reflected in the partnership activity; deals inked in the recent past focused on a diverse range of therapies, involving both international and indigenous stakeholders · The market will receive the required impetus after approval of the first neoantigen targeted therapy; the future growth is likely to be driven by the successful clinical outcomes of the late-stage molecules · In fact, opinions from industry experts confirm the vast potential of this segment of cancer immunotherapy, capable of targeting personalized / off-the-shelf tumour antigens with multiple types of vaccines and therapies providers Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Concept of Immunotherapy 3.3. History of Cancer Immunotherapy 3.4. Limitations of Cancer Immunotherapy 3.5. Targeting Tumor-Specific Neoantigens 3.5.1. Types of Neoantigens 3.5.2. Role of Neoantigens in Cancer Immunotherapy 3.5.3. Neoantigen Targeted Therapies 3.5.3.1. Identification and Selection of Neoantigens 3.5.3.2. Delivery of Neoantigen Targeted Therapies 3.6. Key Challenges and Future Perspectives 4. MARKET OVERVIEW 4.1. Chapter Overview 4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline 4.3. Neoantigen Targeted Therapies: Pipeline Analysis 4.3.1. Analysis by Phase of Development 4.3.2. Analysis by Type of Molecule 4.3.3. Analysis by Type of Immunotherapy 4.3.4. Analysis by Type of Therapy 4.3.5. Analysis by Route of Administration 4.3.6. Analysis by Target Disease Indication 4.3.7. Analysis by Type of Neoantigen 4.3.8. Analysis by Line of Therapy 4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of Immunotherapy and Type of Therapy 4.3.10. Heptagon Representation: Analysis by Phase of Development and Route of Administration 4.4. Neoantigen Targeted Therapies: List of Drug Developers 4.4.1. Analysis by Year of Establishment 4.4.2. Analysis by Company Size and Geographical Location 4.4.3. Leading Developers 4.4.4. Analysis by Geography 4.5 Grid Analysis: Analysis by Target Disease Indication, Company Size and Location 5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES 5.1. Chapter Overview 5.2. Bavarian Nordic 5.2.1. Company Overview 5.2.2. Financial Information 5.2.3. Neoantigen Targeted Therapies Portfolio 5.2.4. Recent Collaborations 5.2.5. Future Outlook 5.3. Genocea Biosciences 5.3.1. Company Overview 5.3.2. Financial Information 5.3.3. Neoantigen Targeted Therapies Portfolio 5.3.4. Recent Collaborations 5.3.5. Future Outlook 5.4. Gradalis 5.4.1. Company Overview 5.4.2. Neoantigen Targeted Therapies Portfolio 5.4.3. Recent Collaborations 5.4.4. Future Outlook 5.5. Immunicum 5.5.1. Company Overview 5.5.2. Financial Information 5.5.3. Neoantigen Targeted Therapies Portfolio 5.5.4. Recent Collaborations 5.5.5. Future Outlook 5.6. Immunovative Therapies 5.6.1. Company Overview 5.6.2. Neoantigen Targeted Therapies Portfolio 5.6.3. Recent Collaborations 5.6.4. Future Outlook 5.7. Iovance Biotherapeutics 5.7.1. Company Overview 5.7.2. Financial Information 5.7.3. Neoantigen Targeted Therapies Portfolio 5.7.4. Recent Collaborations 5.7.5. Future Outlook 5.8. MediGene 5.8.1. Company Overview 5.8.2. Financial Information 5.8.3. Neoantigen Targeted Therapies Portfolio 5.8.4. Recent Collaborations 5.8.5. Future Outlook 5.9. Neon Therapeutics 5.9.1. Company Overview 5.9.2. Financial Information 5.9.3. Neoantigen Targeted Therapies Portfolio 5.9.4. Recent Collaborations 5.9.5. Future Outlook 6. PUBLICATION ANALYSIS 6.1. Chapter Overview 6.2. Methodology 6.3. Neoantigen Targeted Therapies: List of Publications 6.3.1. Analysis by Year of Publication 6.3.2. Analysis by Type of Study 6.3.3. Analysis by Study Objective 6.3.4. Analysis by Affiliated Therapies 6.3.5. Analysis by Target Disease Indication 6.3.6. Key Journals: Analysis by Number of Publications 7. PATENT ANALYSIS 7.1. Chapter Overview 7.2. Scope and Methodology 7.3. Neoantigen Targeted Therapies: Patent Analysis 7.3.1. Analysis by Publication Year 7.3.2. Analysis by Geographical Location 7.3.3. Analysis by CPC Classifications 7.3.4. Analysis by Type of Industry 7.3.5. Emerging Focus Areas 7.3.6. Leading Players: Analysis by Number of Patents 7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis 7.4.1. Analysis by Patent Characteristics 7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis 8. PARTNERSHIPS AND COLLABORATIONS 8.1. Chapter Overview 8.2. Partnership Models 8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations 8.3.1. Analysis by Year of Partnership 8.3.2. Analysis by Type of Partnership 8.3.3. Analysis by Type of Immunotherapy 8.3.4. Analysis by Type of Partnership and Type of Product 8.3.5. Analysis by Type of Partnership and Target Disease Indication 8.3.6. Regional Analysis 8.3.7. Most Active Players: Analysis by Number of Partnerships 9. FUNDING AND INVESTMENT ANALYSIS 9.1. Chapter Overview 9.2. Types of Funding 9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis 9.3.1. Analysis by Number of Instances 9.3.2. Analysis by Amount Invested 9.3.3. Analysis by Type of Funding 9.3.4. Analysis by Amount Invested across Different Types of Therapies 9.3.5. Analysis by Amount Invested across Different Types of Indications 9.3.4. Analysis by Geography 9.3.6. Most Active Players: Analysis by Amount of Funding 9.3.7. Most Active Investors: Analysis by Number of Instances 9.4. Concluding Remarks For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  6. Roots Analysis has done a detailed study on “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights · Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery · Majority of the companies offer structure-based drug design focused on early stage drug discovery of a range of large molecules, including antibodies, proteins and peptides · Featuring the presence of small-mid sized firms, the in silico service provider landscape is well-distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients · Several players involved in this domain n are steadily expanding their capabilities in order to enhance their respective in silico-based service portfolios and maintain a competitive edge in this industry · The integration of novel computational techniques, such as artificial intelligence and cloud-based platforms, with in silico approaches is likely to revolutionize the overall drug discovery process · Service providers are adopting various business strategies in order to continue providing significant cost saving advantages, along with expediting discovery timelines and improving product success · Driven by the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutic areas, the market is expected to witness sustained growth in future · In the long-term, the projected opportunity is anticipated to be well distributed across various geographies, type of sponsors and sizes of in silico service providers Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Drug Discovery and Development Timelines 3.3. Overview of In Silico Drug Discovery Tools 3.3.1. Historical Evolution of the In Silico Approach 3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods 3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development 3.4. Applications of In Silico Tools in the Drug Discovery Process 3.4.1. Target Identification 3.4.1.1. Chemoinformatics-based Tools 3.4.1.2. Network-based Drug Discovery 3.4.1.3. Computational Platforms and Interaction Repositories 3.4.2. Target Validation 3.4.3. Hit Generation 3.4.3.1. High-Throughput Screening 3.4.3.2. Fragment Based Screening 3.4.3.3. Virtual Screening 3.4.4. Hit-to-Lead 3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling 3.4.4.2. Other Novel Approaches 3.4.5. Lead Optimization 3.4.5.1. Pharmacophore Modeling 3.4.5.2. Docking 3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR) 3.4.5.4. Molecular Modeling 3.5. Advantages of using In Silico Tools for Drug Discovery Operations 3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations In-house 3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations 3.8. Concluding Remarks 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Location of Headquarters 4.2.4. Analysis by Company Size and Location of Headquarters 4.2.5. Analysis by Type of Business Model 4.2.6. Analysis by Drug Discovery Steps 4.2.7. Analysis by Type of Large Molecule 4.2.7.1. Analysis by Type of Antibody 4.2.7.2. Analysis by Type of Protein 4.2.8. Analysis by Type of In Silico Approach Used 4.2.9. Analysis by Types of In Silico Services Offered 4.2.10. Analysis by Type of Clientele 4.3. In Silico Drug Discovery Services: List of Software / Technologies 5. KEY INSIGHTS 5.1. Chapter Overview 5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters 5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps 5.4. World Map Representation: Regional Analysis of Outsourcing Activity 5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele 6. COMPANY PROFILES 6.1. Chapter Overview 6.2. Key In Silico Service Providers Based in North America 6.2.1. BioDuro 6.2.1.1. Company Overview 6.2.1.2. Funding and Investment Information 6.2.1.3. In Silico-based Service Portfolio 6.2.1.4. Recent Developments and Future Outlook 6.2.1.5. Peer Group Benchmark Comparison 6.2.2. Creative Biostructure 6.2.2.1. Company Overview 6.2.2.2. Funding and Investment Information 6.2.2.3. In Silico-based Service Portfolio 6.2.2.4. Recent Developments and Future Outlook 6.2.2.5. Peer Group Benchmark Comparison 6.2.3. GenScript 6.2.3.1. Company Overview 6.2.3.2. Funding and Investment Information 6.2.3.3. In Silico-based Service Portfolio 6.2.3.4. Recent Developments and Future Outlook 6.2.3.5. Peer Group Benchmark Comparison 6.2.4. LakePharma 6.2.4.1. Company Overview 6.2.4.2. Funding and Investment Information 6.2.4.3. In Silico-based Service Portfolio 6.2.4.4. Recent Developments and Future Outlook 6.2.4.5. Peer Group Benchmark Comparison 6.3. Leading Players Based in Europe 6.3.1. Abzena 6.3.1.1. Company Overview 6.3.1.2. Funding and Investment Information 6.3.1.3. In Silico-based Service Portfolio 6.3.1.4. Recent Developments and Future Outlook 6.3.1.5. Peer Group Benchmark Comparison 6.3.2. BioNTech 6.3.2.1. Company Overview 6.3.2.2. Funding and Investment Information 6.3.2.3. Recent Developments and Future Outlook 6.3.2.4. Peer Group Benchmark Comparison 6.3.3. Sygnature Discovery 6.3.3.1. Company Overview 6.3.3.2. Funding and Investment Information 6.3.3.3. In Silico-based Service Portfolio 6.3.3.4. Recent Developments and Future Outlook 6.3.3.5. Peer Group Benchmark Comparison 6.4. Leading Players Based in Asia-Pacific 6.4.1. ChemPartner 6.4.1.1. Company Overview 6.4.1.2. In Silico-based Service Portfolio 6.4.1.3. Recent Developments and Future Outlook 6.4.1.4. Peer Group Benchmark Comparison 6.4.2. Sundia MediTech 6.4.2.1. Company Overview 6.4.2.2. Funding and Investment Information 6.4.2.3. In Silico-based Service Portfolio 6.4.2.4. Recent Development and Future Outlook 6.4.2.5. Peer Group Benchmark Comparison 6.4.3. Viva Biotech 6.4.3.1. Company Overview 6.4.3.2. Funding and Investment Information 6.4.3.3. In Silico-based Service Portfolio 6.4.3.4. Recent Development and Future Outlook 6.4.3.5. Peer Group Benchmark Comparison 7. COMPANY COMPETITIVENESS ANALYSIS 7.1. Chapter Overview 7.2. Key Parameters 7.3. Methodology 7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America 7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe 7.6. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World 8. KEY OPPORTUNITY AREAS 8.1. Chapter Overview 8.2. Key Assumptions and Parameters 8.3. Methodology 8.4. Antibodies 8.4.1. Developer Landscape 8.4.1.1. Number of Pipeline Molecules 8.4.1.2. Affiliated Market Size and Growth Rate 8.4.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size 8.5. Peptides 8.5.1. Developer Landscape 8.5.1.1. Number of Pipeline Molecules 8.5.1.2. Affiliated Market Size and Growth Rate 8.5.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size 8.6. Proteins 8.6.1. Developer Landscape 8.6.1.1. Number of Pipeline Molecules 8.6.1.2. Affiliated Market Size and Growth Rate 8.6.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size 8.7. Other Advanced Therapies 8.7.1 Developer Landscape 8.7.1.1 Number of Pipeline Molecules 8.7.1.2 Affiliated Market Size and Growth Rate 8.7.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size 9. EMERGING BUSINESS MODELS AND STRATEGIES 9.1. Chapter Overview 9.2. Key Assumptions and Methodology 9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered 9.3.1. Strategies for Short Term Success 9.3.2. Strategies for Long Term Success 9.4. Concluding Remarks 10.CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES 10.1. Chapter Overview 10.2. Small Molecule and Large Molecule Drugs / Therapies 10.2.1. Comparison of Key Specifications 10.2.2. Comparison of Manufacturing Processes 10.2.3. Comparison of Drug Discovery Processes 10.3. Approaches to Improve Discovery Process of Large Molecules For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  7. Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings. Key Market Insights · Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research · The pipeline features both prebiotic and probiotic drugs, being evaluated across different stages of development; majority of these products are designed for administration via non-invasive routes, such as oral and topical · Microbiome therapeutics have demonstrated the potential to target a range of therapeutic areas; digestive and GI disorders, oncology, infectious diseases, and metabolic disorders are amongst the prime focus areas · Over 10 microbiome-focused disease diagnosis tests are already available in the market; several companies claim to have initiatives in this domain based on different sample types and therapeutic areas · Presently, FMTs are the only commercially available microbiome products for the treatment of recurrent CDIs; in fact, several trials evaluating FMTs, sponsored by non-industry players, have been registered in the past decade · Over time, well funded start-ups have initiated product development programs, having invested significant time and effort to explore the applicability of microbiome therapeutics across various indications · Several big pharmaceutical players have partnered with smaller and dedicated microbiome-based therapy / diagnostic developers in order to expand their respective capabilities in this upcoming field of pharmacology · Contract service providers have become an integral part of microbiome supply chain owing to their technical expertise and ability to overcome existing challenges related to both R&D and production · Prevalent trends indicate that microbiome drugs and diagnostics market is poised to grow significantly; the forecasted opportunity is anticipated to be distributed across different target indications and regions · Microbiome therapeutic developers are expected to witness significant momentum, in terms of revenues generation, as multiple late stage molecules for the treatment of different clinical conditions get commercialized Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Concept of Microbiota and Microbiome 3.2.1. Discovery of the Human Microbiome 3.2.2. Functions of the Human Microbiome 3.3. Overview of Gut Flora 3.3.1. Role of Gut Flora in Healthy Individuals 3.3.2. Factors Affecting Gut Flora 3.3.2.1. Antibiotic Consumption 3.3.2.2. Age and Pregnancy 3.3.2.2.1. Mode of Childbirth 3.3.2.2.2. Type of Feeding 3.3.2.2.3. Antibiotic Consumption by Mother 3.3.2.3. Stress-related Factors 3.3.2.4. Dietary Factors 3.3.2.5. Impact of Lifestyle 3.4. The Microbiome and Disease 3.4.1. Cancer 3.4.2. Inflammatory Bowel Disease (IBD) 3.4.3. Obesity 3.4.4. Parkinson’s Disease 3.4.5. Type-II Diabetes 3.4.6. Other Disease Indications 3.5. Impact of Microbiota on Drug Pharmacokinetics 3.6. Impact of Microbiota on Therapeutic Outcomes 3.7. Microbiome Therapeutics 3.7.1. Probiotics 3.7.1.1. Beneficial Bacterial Strains 3.7.1.1.1. Lactobacilli 3.7.1.1.2. Bifidobacteria 3.7.1.1.3. Others 3.7.1.2. Key Therapeutic Areas 3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD) 3.7.1.2.2. Bacterial Vaginosis 3.7.1.2.3. High Blood Pressure 3.7.1.2.4. Hypercholesterolemia 3.7.1.2.5. Infectious Childhood Diarrhea (ICD) 3.7.1.2.6. Inflammatory Bowel Disease (IBD) 3.7.1.2.7. Lactose Intolerance 3.7.1.2.8. Vitamin Production 3.7.1.2.9. Weight Management 3.7.1.3. Side Effects of Probiotics 3.7.2. Prebiotics 3.7.2.1. Sources of Prebiotics 3.7.2.2. Types of Prebiotics 3.7.2.2.1. Fructo-Oligosaccharides (FOS) 3.7.2.2.2. Galacto-Oligosaccharides (GOS) 3.7.2.2.3. Inulin 3.7.2.3. Key Therapeutic Areas 3.7.2.3.1. Antibiotic Associated Diarrhea (AAD) 3.7.2.3.2. Constipation 3.7.2.3.3. Gastrointestinal Disorders 3.7.2.3.4. Dysbiosis 3.7.2.4. Side Effects of Prebiotics 3.8. The Human Microbiome Project (HMP) 3.8.1. Project Approach 3.8.2. Project Initiatives 3.8.3. Project Achievements 3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs) 3.10. Key Challenges in the Development of Microbiome Therapeutics 3.11. Future Perspectives 4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Microbiome Therapeutics: Clinical Pipeline 4.2.1. Analysis by Phase of Development 4.2.2. Analysis by Type of Molecule 4.2.3. Analysis by Type of Therapy 4.2.4. Analysis by Target Indication 4.2.5. Analysis by Therapeutic Area 4.2.6. Analysis by Dosing Frequency 4.2.7. Analysis by Route of Administration 4.2.8. Analysis by Drug Formulation 4.3. Microbiome Therapeutics: Early-Stage Pipeline 4.3.1. Analysis by Phase of Development 4.3.2. Analysis by Type of Molecule 4.3.3. Analysis by Type of Therapy 4.3.4. Analysis by Target Indication 4.3.5. Analysis by Therapeutic Area 4.4. Microbiome Therapeutics: List of Drug Developers 4.4.1. Analysis by Year of Establishment 4.4.2. Analysis by Location of Headquarters 4.4.3. Analysis by Company Size 4.4.4. Analysis by Company Size and Location of Headquarters 4.4.5. Leading Drug Developers: Analysis by Number of Microbiome Therapeutics 4.5. Grid Analysis: Microbiome and Key Therapeutic Areas 4.6. Microbiome Therapeutics: List of Discontinued Drugs 4.7. Emerging Role of Microbiome in Gut-Brain Axis 4.8. Microbiome Therapeutics: List of Technology Platforms 5. COMPANY AND DRUG PROFILES 5.1. Chapter Overview 5.2. 4D Pharma 5.2.1. Company Overview 5.2.2. Microbiome-based Product Portfolio 5.2.2.1. Blautix® 5.2.2.1.1. Drug Overview 5.2.2.1.2. Current Status of Development 5.2.2.1.3. Clinical Studies 5.2.2.1.4. Clinical Trial End-Point Analysis 5.2.3. Recent Developments and Future Outlook 5.3. Armata Pharmaceuticals 5.3.1. Company Overview 5.3.2. Microbiome-Based Product Portfolio 5.3.2.1. C16G2 5.3.2.1.1. Drug Overview 5.3.2.1.2. Current Status of Development 5.3.2.1.3. Clinical Studies 5.3.2.1.4. Clinical Trial End-Point Analysis 5.3.3. Recent Developments and Future Outlook 5.4. Evelo Biosciences 5.4.1. Company Overview 5.4.2. Microbiome-Based Product Portfolio 5.4.2.1. EDP1503 5.4.2.1.1. Drug Overview 5.4.2.1.2. Current Status of Development 5.4.2.1.3. Clinical Studies 5.4.2.1.4. Clinical Trial End-Point Analysis 5.4.3. Recent Developments and Future Outlook 5.5. Rebiotix (Acquired by Ferring Pharmaceuticals) 5.5.1. Company Overview 5.5.2. Financial Information 5.5.3. Microbiome-Based Product Portfolio 5.5.3.1. RBX2660 5.5.3.1.1. Drug Overview 5.5.3.1.2. Current Status of Development 5.5.3.1.3. Clinical Studies 5.5.3.1.4. Clinical Trial End-Point Analysis 5.5.4. Recent Developments and Future Outlook 5.6. Seres Therapeutics 5.6.1. Company Overview 5.6.2. Financial Information 5.6.3. Microbiome-Based Product Portfolio 5.6.3.1. SER-109 5.6.3.1.1. Drug Overview 5.6.3.1.2. Current Status of Development 5.6.3.1.3. Clinical Studies 5.6.3.1.4. Clinical Trial End-Point Analysis 5.6.3.2. SER-287 5.6.3.2.1. Current Status of Development 5.6.3.2.2. Clinical Studies 5.6.3.2.3. Clinical Trial End-Point Analysis 5.6.4. Recent Developments and Future Outlook 5.7. Vedanta Biosciences 5.7.1. Company Overview 5.7.2. Microbiome-Based Product Portfolio 5.7.2.1. VE303 5.7.2.1.1. Drug Overview 5.7.2.1.2. Current Status of Development 5.7.2.1.3. Clinical Studies 5.7.3.1.4. Clinical Trial End-Point Analysis 5.7.3. Recent Developments and Future Outlook 6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE 6.1. Chapter Overview 6.2. Overview of Microbiome Diagnostic Tests 6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products 6.3.1. Analysis by Stage of Development 6.3.2. Analysis by Type of Sample Required 6.3.3. Analysis by Target Indication 6.3.4. Analysis by Therapeutic Area 6.3.5. Analysis by Purpose 6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers 6.4.1. Analysis by Year of Establishment 6.4.2. Analysis by Location of Headquarters 6.4.3. Analysis by Company Size 6.4.4. Analysis by Company Size and Location of Headquarters 6.4.5. Leading Diagnostic Developers: Analysis by Number of Microbiome Diagnostics 6.5. Profiles of Prominent Diagnostic Developers 6.5.1. Enterome Bioscience 6.5.1.1. Company Overview 6.5.1.2. Service Portfolio 6.5.2. Vaiomer 6.5.2.1. Company Overview 6.5.2.2. Service Portfolio 6.6. Overview of Microbiome Screening / Profiling Tests 6.6.1. List of Microbiome Screening / Profiling Tests 6.6.2. List of Microbiome Screening / Profiling Test Developers 7. FECAL MICROBIOTA THERAPY (FMT) 7.1. Chapter Overview 7.2. Introduction to FMT 7.3. Historical Overview 7.4. FMT: Procedure and Clinical Relevance 7.4.1. Donor Selection 7.4.2. Administration Procedure 7.4.3. Routes of Administration 7.4.4. Consequences and Adverse Events 7.4.5. Clinical Guidelines Associated with FMT 7.5. Regulatory Guidelines Related to FMT 7.6. Insurance Coverage for FMT 7.7. FMT: Competitive Landscape 7.7.1. Marketed / Development Pipeline (Industry Players) 7.7.1.1. Analysis by Phase of Development 7.7.1.2. Analysis by Therapeutic Area 7.7.1.3. Analysis by Route of Administration 7.7.2. List of Developers (Industry Players) 7.7.2.1. Analysis by Year of Establishment 7.7.2.2. Analysis by Location of Headquarters 7.7.2.3. Analysis by Company Size 7.8. Clinical Trial Analysis (Non-Industry Sponsored) 7.8.1. Scope and Methodology 7.8.2. List of Clinical Trials 7.8.2.1. Analysis by Trial Registration Year 7.8.2.2. Analysis by Trial Status 7.8.2.3. Analysis by Phase of Development 7.8.2.4. Analysis by Patients Enrolled 7.8.2.5. Analysis of Number of Patients Enrolled by Trial Registration Year 7.8.2.6. Analysis by Therapeutic Area 7.8.2.7. Analysis by Popular Target Indications 7.8.2.8. Analysis by Trial Registration Year and Recruitment Status 7.8.2.9. Analysis by Study Design 7.8.2.10. Leading Non-Industry Players: Analysis by Number of Trials 7.8.2.11. Geographical Analysis by Number of Clinical Trials 7.8.2.12. Geographical Analysis by Enrolled Patient Population 7.8.2.13. Analysis by Type of Sponsor / Collaborator 7.8.2.14. Analysis by Trial Focus 7.8.2.15. Key Clinical Trials 7.9. Stool Banks 7.9.1. Introduction to Stool Banks 7.9.2. List of Stool Banks 7.9.3. Profiles of Prominent Stool Banks 7.9.3.1. AdvancingBio 7.9.3.1.1. Overview 7.9.3.1.2. Fecal Microbiota Preparation 7.9.3.2. Asia Microbiota bank 7.9.3.2.1. Overview 7.9.3.2.2. Fecal Microbiota Preparation 7.9.3.3. Enterobiotix 7.9.3.3.1. Overview 7.9.3.3.2. Fecal Microbiota Preparation 7.9.3.4. Flora Medicine 7.9.3.4.1. Overview 7.9.3.4.2. Fecal Microbiota Preparation 7.9.3.5. OpenBiome 7.9.3.5.1. Overview 7.9.3.5.2. Fecal Microbiota Preparation 8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX 8.1. Chapter Overview 8.2. AC Matrix: An Overview 8.2.1. Strong Opportunity Areas 8.2.2. Average Opportunity Areas 8.2.3. Weak Opportunity Areas 8.3. AC Matrix: Analytical Methodology 8.4. AC Matrix: Plotting the Information 8.5. AC Matrix: Analyzing the Data 8.5.1. Strong Opportunity Areas 8.5.2. Average Opportunity Areas 8.5.3. Weak Opportunity Areas 9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Initiatives of Big Pharmaceutical Players 9.3.1. Analysis by Portfolio Diversity 9.3.2. Analysis by Phase of Development 9.3.3. Analysis by Type of Molecule 9.3.4. Analysis by Type of Therapy 9.3.5. Analysis by Diversity of Therapeutic Areas 9.4. Benchmark Analysis of Big Pharmaceutical Players 9.4.1. Spider Web Analysis: Company A 9.4.2. Spider Web Analysis: Company B 9.4.3. Spider Web Analysis: Company C 9.4.4. Spider Web Analysis: Company D 9.4.5. Spider Web Analysis: Company E 9.4.6. Spider Web Analysis: Company F 9.4.7. Spider Web Analysis: Company G 9.4.8. Spider Web Analysis: Company H 9.4.9. Spider Web Analysis: Company I 9.4.10. Spider Web Analysis: Company J 9.4.11. Spider Web Analysis: Company K 10.START-UP HEALTH INDEXING 10.1. Chapter Overview 10.2. Scope and Methodology 10.3. Benchmark Analysis of Start-ups 10.3.1. Benchmark Analysis by Portfolio Diversity 10.3.2. Benchmark Analysis by Phase of Development 10.3.3. Benchmark Analysis by Diversity in Therapeutic Areas 10.3.4. Benchmark Analysis by Funding Amount 10.3.5. Benchmark Analysis by Number of Investors 10.3.6. Benchmark Analysis by Progression in Funding 10.3.7. Benchmark Analysis by Partnership Activity 10.3.8. Benchmark Analysis by Patent Portfolio 10.3.9. Start-up Health Indexing: Roots Analysis Perspective 10.3.9.1. Short Profiles of Top Five Players 10.3.9.1.1. Evelo Biosciences 10.3.9.1.2. AOBiome Therapuetics 10.3.9.1.3. SFA Therapeutics 10.3.9.1.4. Azitra 10.3.9.1.5. Axial Biotherapeutics 11.KEY THERAPEUTIC AREAS 11.1. Chapter Overview 11.2. Metabolic Disorders 11.2.1. Diabetes 11.2.1.1. Disease Description 11.2.1.2. Associated Health Risks / Complications 11.2.1.3. Epidemiology 11.2.1.4. Disease Diagnosis 11.2.1.5. Current Treatment Options 11.2.1.5.1. Insulin Therapies 11.2.1.5.2. Non-Insulin Therapies 11.2.1.6. Side Effects of Current Treatment Options 11.2.1.7. Microbiome Therapeutics for Diabetes 11.2.2. Lactose Intolerance 11.2.2.1. Disease Description 1.2.2.2. Epidemiology 11.2.2.2. Current Treatment Options 11.2.2.3. Microbiome Therapeutics for Lactose Intolerance 11.2.3. Nonalcoholic Steatohepatitis (NASH) 11.2.3.1. Disease Description 11.2.3.2. Epidemiology 11.2.3.3. Current Treatment Options 11.2.3.4. Microbiome Therapeutics for NASH 11.2.4. Primary Hyperoxaluria 11.2.4.1. Disease Description 11.2.4.2. Epidemiology 11.2.4.3. Current Treatment Options 11.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria 11.2.5. Obesity 11.2.5.1. Disease Description 11.2.5.2. Epidemiology 11.2.5.3. Current Treatment Options 11.2.5.4. Side Effects of Current Treatment Options 11.2.5.5. Microbiome Therapeutics for Obesity 11.3. Digestive and Gastrointestinal Disorders 11.3.1. Crohn’s Disease 11.3.1.1. Disease Description 11.3.1.2. Epidemiology 11.3.1.3. Current Treatment Options 11.3.1.4. Side Effects of Current Treatment Options 11.3.1.5. Microbiome Therapeutics for Crohn’s Disease 11.3.2. Irritable Bowel Syndrome (IBS) 11.3.2.1. Disease Description 11.3.2.2. Epidemiology 11.3.2.3. Current Treatment Options 11.3.2.4. Microbiome Therapeutics for IBS 11.3.3. Ulcerative Colitis 11.3.3.1. Disease Description 11.3.3.2. Epidemiology 11.3.3.3. Current Treatment Options 11.3.3.4. Side Effects of Current Treatment Options 11.3.3.5. Microbiome Therapeutics for Ulcerative Colitis 11.4. Oncological Indications 11.4.1. Colorectal Cancer 11.4.1.1. Disease Description 11.4.1.2. Epidemiology 11.4.1.3. Current Treatment Options 11.4.1.4. Side Effects of Current Treatments 11.4.1.5. Microbiome Therapeutics for Colorectal Cancer 11.4.2. Lung Cancer 11.4.2.1. Disease Description 11.4.2.2. Epidemiology 11.4.2.3. Current Treatment Options 11.4.2.4. Side Effects of Current Treatment Options 11.4.2.5. Microbiome Therapeutics for Lung Cancer 11.5. Dermatological Disorders 11.5.1. Acne Vulgaris 11.5.1.1. Disease Description 11.5.1.2. Epidemiology 11.5.1.3. Current Treatment Options 11.5.1.4. Side Effects of Current Treatment Options 11.5.1.5. Microbiome Therapeutics for Acne Vulgaris 11.6. Infectious Diseases 11.6.1. Clostridium Difficile Infections (CDIs) 11.6.1.1. Description 11.6.1.2. Epidemiology 11.6.1.3. Disease Diagnosis 11.6.1.4. Current Treatment Options 11.6.1.5. Side Effects of Current Treatment Options 11.6.1.6. Microbiome Therapeutics for CDI 11.6.2. Bacterial Vaginosis 11.6.2.1. Disease Description 11.6.2.2. Epidemiology 11.6.2.3. Current Treatment Options 11.6.2.4. Side Effects of Current Treatment Options 11.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis 12.FUNDING AND INVESTMENT ANALYSIS 12.1. Chapter Overview 12.2. Types of Funding 12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments 12.3.1. Analysis by Number of Instances 12.3.2. Analysis by Amount Invested 12.3.3. Analysis by Type of Funding 12.3.4. Analysis by Type of Company 12.3.5. Analysis by Purpose of Funding 12.3.6. Analysis by Type of Molecule 12.3.7. Analysis by Target Indication 12.3.8. Analysis by Therapeutic Area 12.3.9. Analysis by Geography 12.3.10. Most Active Players 12.3.11. Most Active Investors 12.3.12. Analysis by Type of Investors 12.3.13. Analysis by Location of Investors 12.4. Concluding Remarks 13.CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS 13.1. Chapter Overview 13.2. Manufacturing Microbiome Therapeutics 13.2.1. Key Steps Involved 13.2.2. Associated Challenges 13.2.3. Growing Demand for Contract Manufacturing Services 13.2.4. Contract Manufacturing Organizations (CMOs) 13.2.4.1. Introduction to Contract Manufacturing 13.2.4.2. List of Organizations Offering Services for Microbiome Therapeutics 13.2.5. In-House Manufacturers 13.2.5.1. Introduction to In-House Manufacturing 13.2.5.2. List of In-House Manufacturers 13.3. Microbiome Therapeutics-related R&D 13.3.1. Growing Demand for Contract Research Services 13.3.2. Contract Research Organizations (CROs) 13.3.2.1. Introduction to Contract Research 13.3.2.2. List of Organizations Offering Services for Microbiome Therapeutics 13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner 14.BIG DATA AND MICROBIOME THERAPEUTICS 14.1. Chapter Overview 14.2. Introduction to Big Data 14.3. Internet of Things 14.4. Growing Interest in Big Data: Google Trends Analysis 14.5. Key Application Areas 14.6. Big Data in Microbiome Research 14.6.1. Microbiome Data and Personalized Medicine 14.6.2. Microbiome-related Data Management Challenges 14.6.3. National Microbiome Data Center 14.7. Big Data Services for Microbiome Research: List of Companies 14.8. Big Data Services for Microbiome Research: Profiles of Key Players 14.8.1. Human Longevity 14.8.1.1. Company Overview 14.8.1.2. Technology and Service Portfolio 14.8.1.3. Recent Developments 14.8.2. Resilient Biotics 14.8.2.1. Company Overview 14.8.2.2. Technology and Service Portfolio 14.8.2.3. Recent Developments 14.8.3. Resphera Biosciences 14.8.3.1. Company Overview 14.8.3.2. Technology and Service Portfolio 15.MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS 15.1. Chapter Overview 15.2. Scope and Limitations 15.3. Forecast Methodology 15.4. Overall Microbiome Therapeutics Market, 2019-2030 15.4.1. Microbiome Therapeutics Market: Distribution by Type of Therapy, 2025 and 2030 15.4.1.1. Microbiome Therapeutics Market for Prescription Drugs, 2019-2030 15.4.1.2. Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030 15.4.1.3. Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030 15.4.2. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2025 and 2030 15.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2019-2030 15.4.2.2. Microbiome Therapeutics Market for Biologics, 2019-2030 15.4.3. Microbiome Therapeutics Market: Distribution by Target Indication, 2025 and 2030 15.4.3.1. Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030 15.4.3.2. Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030 15.4.3.3. Microbiome Therapeutics Market for CDI, 2019-2030 15.4.3.4. Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030 15.4.3.5. Microbiome Therapeutics Market for Dental Caries, 2019-2030 15.4.3.6. Microbiome Therapeutics Market for Diabetes, 2019-2030 15.4.3.7. Microbiome Therapeutics Market for IBS, 2019-2030 15.4.3.8. Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030 15.4.3.9. Microbiome Therapeutics Market for Lung Cancer, 2019-2030 15.4.3.10. Microbiome Therapeutics Market for NASH, 2019-2030 15.4.3.11. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030 15.4.3.12. Microbiome Therapeutics Market for Psoriasis, 2019-2030 15.4.3.13. Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030 15.4.4. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025 and 2030 15.4.4.1. Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030 15.4.4.2. Microbiome Therapeutics Market for Dental Disorders, 2019-2030 15.4.4.3. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030 15.4.4.4. Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030 15.4.4.5. Microbiome Therapeutics Market for Infectious Diseases, 2019-2030 15.4.4.6. Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030 15.4.4.7. Microbiome Therapeutics Market for Oncology, 2019-2030 15.4.5. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2025 and 2030 15.4.5.1. Microbiome Therapeutics Market in North America, 2019-2030 15.4.5.2. Microbiome Therapeutics Market in Europe, 2019-2030 15.4.5.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030 15.4.6. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2025 and 2030 15.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030 For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  8. Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights · Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs · The market is fragmented, featuring the presence of both established players and small firms based in different geographies that claim to be capable of manufacturing ophthalmic products · Presently, majority of the CMOs are offering services for ophthalmic drug FDFs packaged in a variety of formats; popular types of containers include glass / plastic bottles, ointment tubes and ampoules / vials · In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities · Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and maintain a competitive edge · In the past few years, over 10,700 trials, enrolling approximately 4.6 million patients, suffering from a wide range of chronic eye conditions, have been registered across the globe by different sponsors · Most of the installed, global ophthalmic drug manufacturing capacity belongs to larger and more established CMOs, accounting for over 80% of available capacity across various geographies · The demand for manufacturing services for ophthalmic drug products is expected to increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure consistent supply · We expect ophthalmic drug developers to continue to outsource their development and manufacturing operations in the short to mid-term, causing service-based revenues to grow at an annualized rate of over 8% · In the long-term, the projected opportunity is anticipated to be well distributed across various packaging formats, scales of operation and sizes of contract service providers · Eminent representatives from prominent ophthalmic drug contract manufacturing companies confirm the importance of outsourcing, highlighting prevalent and anticipated trends within this domain Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Context and Background 3.2. Introduction to Ophthalmology 3.2.1. Chronic Eye Conditions and Associated Economic Burden 3.3. Common Ophthalmic Drug Dosage Forms 3.3.1. Types of Oral Drug Formulations 3.3.1.1. Tablets 3.3.1.2. Capsules 3.3.1.3. Eye Supplements 3.3.2. Types of Semi-solid Formulations 3.3.2.1. Ointments 3.5.2.2. Gels 3.5.2.3. Emulsions 3.3.3. Types of Liquid Drug Formulations 3.3.3.1. Solutions 3.3.3.2. Suspensions 3.5.3.1. Sterile Injectables 3.3.4. Intraocular Inserts 3.4. Common Primary Packaging Formats for Ophthalmic Drugs 3.5. Overview of Contract Manufacturing 3.6. Outsourcing in the Ophthalmology Industry 3.6.1. Need for Outsourcing 3.6.2. Commonly Outsourced Operations 3.6.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner 3.6.4. Advantages of Outsourcing Manufacturing Operations 3.6.5. Challenges Associated with Ophthalmic Drugs Contract Manufacturing 3.6.6. Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing 3.6.7. Recent Developments and Upcoming Trends 4. CURRENT MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Ophthalmic Drug Contract Manufacturers: Overall Market Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Scale of Operation 4.2.4. Analysis by Geographical Location 4.2.5. Analysis by Location of Manufacturing Facilities 4.2.6. Analysis by Type of Product 4.2.7. Analysis by Type of FDF Manufactured 4.2.8. Analysis by Type of Primary Packaging 4.2.9. Analysis by Type of Service(s) Offered 4.2.10. Analysis by Regulatory Accreditations / Certifications 5. COMPANY COMPETITVENESS ANALYSIS 5.1. Chapter Overview 5.2. Key Assumptions and Methodology 5.3. Competitiveness Analysis: Ophthalmic API Contract Manufacturers 5.3.1. Ophthalmic API Contract Manufacturers in North America 5.3.2. Ophthalmic API Contract Manufacturers in Europe 5.3.3. Ophthalmic API Contract Manufacturers in Asia-Pacific 5.4. Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers 5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America 5.4.2. Ophthalmic Drug FDF Contract Manufacturers in Europe 5.4.3. Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific 6. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES 6.1. Chapter Overview 6.2. Akorn 6.2.1. Company Overview 6.2.2. Financial Information 6.2.3. Service Portfolio 6.2.4. Recent Developments and Future Outlook 6.3. Catalent 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. Service Portfolio 6.2.4. Recent Developments and Future Outlook 6.4. Cayman Chemical 6.4.1. Company Overview 6.4.2. Service Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. Pillar5 Pharma 6.5.1. Company Overview 6.5.2. Service Portfolio 6.5.3. Recent Developments and Future Outlook 6.6. Sterling Pharmaceutical Services 6.6.1. Company Overview 6.6.2. Service Portfolio 6.6.3. Recent Developments and Future Outlook 7. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES 7.1. Chapter Overview 7.2. FARMIGEA 7.2.1. Company Overview 7.2.2. Service Portfolio 7.2.3. Recent Developments and Future Outlook 7.3. Lomapharm 7.3.1. Company Overview 7.3.2. Service Portfolio 7.3.3 Recent Developments and Future Outlook 7.4. Medichem 7.4.1. Company Overview 7.4.2. Service Portfolio 7.4.3. Recent Developments and Future Outlook 7.5. Recipharm 7.5.1. Company Overview 7.5.2. Financial Information 7.5.3. Service Portfolio 7.5.4. Recent Developments and Future Outlook 7.6. Salvat 7.6.1. Company Overview 7.6.2 Service Portfolio 7.6.2. Recent Developments and Future Outlook 8. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES 8.1. Chapter Overview 8.2. Akums 8.2.1. Company Overview 8.2.2. Service Portfolio 8.2.3. Recent Developments and Future Outlook 8.3. Bal Pharma 8.3.1. Company Overview 8.3.2. Financial Information 8.3.3. Service Portfolio 8.2.4. Recent Developments and Future Outlook 8.4. Entod Pharmaceuticals 8.4.1. Company Overview 8.4.2. Service Portfolio 8.4.3. Recent Developments and Future Outlook 8.5. Glenmark Pharmaceuticals 8.5.1. Company Overview 8.5.2. Service Portfolio 8.5.3. Recent Developments and Future Outlook 8.6. Indiana Ophthalmics 8.6.1. Company Overview 8.6.2. Service Portfolio 8.6.3. Recent Developments and Future Outlook 8.7. Sunways India 8.7.1. Company Overview 8.7.2. Service Portfolio 8.7.3. Recent Developments and Future Outlook 9. CLINICAL TRIAL ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Ophthalmic Drug Trial Analysis 9.3.1. Analysis by Trial Registration Year 9.3.2. Geographical Analysis by Number of Clinical Trials 9.3.3. Geographical Analysis by Enrolled Patient Population 9.3.4. Analysis by Phase of Development 9.3.5. Analysis by Trial Recruitment Status 9.3.6. Analysis by Type of Sponsor / Collaborator 9.3.7. Most Active Players in Terms of Number of Registered Trials 9.3.8. Analysis by Type of Intervention 9.3.9. Analysis by Trial Focus 9.3.10. Analysis by Target Indication 9.3.11. Benchmark Analysis of Active Industry Players 10.CAPACITY ANALYSIS 10.1. Chapter Overview 10.2. Key Assumptions and Methodology 10.3. Ophthalmic API Contract Manufacturers: Global Production Capacity 10.3.1. Analysis by Geography 10.3.1.1. Overall Production Capacity in North America 10.3.1.2. Overall Production Capacity in Europe 10.3.1.3. Overall Production Capacity in Asia-Pacific 10.3.1.4. Overall Production Capacity in Rest of the World 10.3.2. Analysis by Scale of Operation 10.3.2.1. Overall Clinical Scale Production Capacity 10.3.2.2. Overall Commercial Scale Production Capacity 10.3.2.3. Both Clinical and Commercial Scale Production Capacity 10.3.3. Analysis by Company Size 10.3.3.1. Overall Production Capacity of Small-sized Companies 10.3.3.2. Overall Production Capacity of Mid-sized Companies 10.3.3.3. Overall Production Capacity of Large Companies 10.3.3.4. Overall Production Capacity of Very Large Companies 10.4. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity 10.4.1. Analysis by Geography 10.4.1.1. Overall Production Capacity in North America 10.4.1.2. Overall Production Capacity in Europe 10.4.1.3. Overall Production Capacity in Asia-Pacific 10.4.1.4. Overall Production Capacity in Rest of the World 10.4.2. Analysis by Scale of Operation 10.4.2.1. Overall Clinical Scale Production Capacity 10.4.2.2. Overall Commercial Scale Production Capacity 10.4.2.3. Both Clinical and Commercial Scale Production Capacity 10.4.3. Analysis by Company Size 10.4.3.1. Overall Production Capacity of Small-sized Companies 10.4.3.2. Overall Production Capacity of Mid-sized Companies 10.4.3.3. Overall Production Capacity of Large Companies 10.4.3.4. Overall Production Capacity of Very Large Companies 10.4.4. Analysis by Type of Primary Packaging 10.4.4.1. Overall Production Capacity of Ampoules / Vials 10.4.4.2. Overall Production Capacity of Glass / Plastic Bottles 10.4.4.3. Overall Production Capacity of Ointment Tubes 10.4.4.4. Overall Production Capacity of Blister Packing 10.4.4.5. Overall Production Capacity of Other Packaging Forms 11.DEMAND ANALYSIS 11.1. Chapter Overview 11.2. Key Assumptions and Methodology 11.3. Global Commercial Demand for Ophthalmic Drugs Contract Manufacturing 11.3.1. Commercial Demand for Ophthalmic API Contract Manufacturing 11.3.1.1. Analysis by Geography 11.3.1.2. Analysis by Target Indication 11.3.2. Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing 11.3.2.1. Analysis by Geography 11.3.2.2. Analysis by Target Indication 11.3.2.3. Analysis by Type of Primary Packaging 11.4. Global Clinical Demand for Ophthalmic Drugs Contract Manufacturing 11.4.1. Clinical Demand for Ophthalmic API Contract Manufacturing 11.4.1.1. Analysis by Geography 11.4.1.2. Analysis by Target Indication 11.4.2. Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing 11.4.2.1. Analysis by Geography 11.4.2.2. Analysis by Target Indication 11.4.2.3. Analysis by Type of Primary Packaging 11.5. Demand and Supply Analysis 12.MARKET FORECAST 12.1. Chapter Overview 12.2. Key Assumptions and Forecast Methodology 12.3. Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030 12.4. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product 12.4.1. Ophthalmic API Contract Manufacturing Market, 2020-2030 12.4.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030 12.4.2.1. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured 12.4.2.1.1. Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030 12.4.2.1.2. Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030 12.4.2.1.3. Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030 12.4.2.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging 12.4.2.2.1. Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030 12.4.2.2.2. Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030 12.4.2.2.3. Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030 12.4.2.2.4. Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030 12.4.2.2.5. Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030 12.5. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication 12.5.1. Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030 12.5.2. Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030 12.5.3. Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030 12.5.4. Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030 12.6. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation 12.6.1. Ophthalmic Drugs Contract Manufacturing Market for Clinical Scale Operations, 2020-2030 12.6.2. Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 12.6.3. Ophthalmic Drugs Contract Manufacturing Market for Both Clinical and Commercial Scale Operations, 2020-2030 12.7. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Size of Manufacturers 12.7.1. Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030 12.7.2. Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030 12.7.3. Ophthalmic Drugs Contract Manufacturing Market for Large Companies, 2020-2030 12.7.4. Ophthalmic Drugs Contract Manufacturing Market for Very Large Companies, 2020-2030 12.8. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions 12.8.1. Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030 12.8.1.1. Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030 12.8.1.2. Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030 12.8.1.3. Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-203 12.8.2. Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030 12.8.2.1. Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030 12.8.2.2. Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030 12.8.2.3. Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030 12.8.2.4. Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030 12.8.2.5. Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030 12.8.2.6. Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030 12.8.3. Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030 12.8.3.1. Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030 12.8.3.2. Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030 12.8.3.3. Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030 12.8.3.4. Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030 12.8.3.5. Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 13.CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE OPHTHALMIC DRUGS / THERAPIES 13.1. Chapter Overview 13.2. Small Molecule Drugs and Biologics in Ophthalmology 13.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics 13.2.2. Comparison of Key Specifications 13.2.3. Comparison of Manufacturing Processes 13.2.4. Comparison of Key Manufacturing-related Challenges 14.SWOT ANALYSIS 14.1. Chapter Overview 14.2. Comparison of SWOT Factors 15.SURVEY ANALYSIS 15.1. Chapter Overview 15.2. Overview of Respondents 15.2.1. Seniority Level of Respondents 15.3. Survey Insights 15.3.1. Type of Product 15.3.2. Type of Primary Packaging 15.3.3. Scale of Operation 15.3.4. Manufacturing Capacity 15.3.5. Location of Manufacturing Facilities 15.3.6. Regulatory Accreditations / Certifications of Manufacturing Facilities 15.3.7. Extent of Outsourcing 15.3.8. Current Market Opportunity 16.EXECUTIVE INSIGHTS 16.1. Chapter Overview 16.2. Caplin Point Laboratories 16.2.1. Company Snapshot 16.2.2. Interview Transcript: Ashok Partheeban, Director, Latin American Operations and Vivek Partheeban, Chief Operating Officer 16.3. Gland Pharma 16.3.1. Company Snapshot 16.3.2. Interview Transcript: Iranna Bavalatti, Head of Manufacturing Science and Technology 16.4. Selvok Pharmaceutical 16.4.1. Company Snapshot 16.4.2. Interview Transcript: Rahul Gupta, Chief Executive Officer 16.5. Phytex Australia 16.4.1. Company Snapshot 16.4.2. Interview Transcript: Stuart Smith, Managing Director 17.FUTURE GROWTH OPPORTUNITIES 17.1. Chapter Overview 17.2. Integration / Adoption of New and Innovative Technologies 17.3. Capability and Expertise Expansions by CMOs 17.4. Offshoring Outsourcing Activities 17.5. Growing Investments in Existing Infrastructure 17.6. Evolving Client / Sponsor and CMO / CDMO Relationships 17.7. Challenges Faced by Both Sponsors and Service Providers 17.7.1. Concerns Related to Single Use Systems 17.7.2. Concerns Related to Capacity Fluctuations 18.APPENDIX 1: LIST OF OPHTHALMIC MEDICAL DEVICE CONTRACT MANUFACTURERS 19.APPENDIX 2: TABULATED DATA 20.APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  9. The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.” The report features an extensive study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications. The study includes in-depth analyses, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, it includes: · A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. · A competitiveness analysis of prominent oligonucleotide manufacturers, featuring insightful pictorial summaries and representations. · Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides. · An analysis of the various partnerships pertaining to oligonucleotide manufacturing, which have been established in the recent past. · An analysis of the various expansion initiatives undertaken by service providers engaged in this domain. · A detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products. · An estimate of the overall, annual capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain. · An informed estimate of the annual clinical and commercial demand for oligonucleotides. · A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework. · A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Type of Manufacturing · Custom Manufacturing · Large-scale Manufacturing Type of Oligonucleotides Manufactured · Antisense Oligonucleotides · miRNAs · shRNAs · siRNAs · Other Oligonucleotides Scale of Operation · Clinical · Commercial Purpose of Production · In-house · Outsourced Target Therapeutic Area · Autoimmune Disorders · Cardiovascular Disorders · Genetic Disorders · Infectious Diseases · Metabolic Disorders · Neuromuscular Disorders · Oncological Disorders · Ophthalmic Disorders · Other Therapeutic Areas Size of manufacturer · Small · Mid-sized · Large Key Geographical Region · North America · Europe · Asia-Pacific and Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies · Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Lifesciences) · Tobias Pohlmann (Founder and Managing Director, BianoScience) Key companies covered in the report · Agilent Technologies · Ajinomoto Bio-Pharma Services · BioSpring · CordenPharma · Integrated DNA Technologies · Kaneka Eurogentec · LGC Biosearch Technologies · Microsynth · Nitto Denko Avecia · Sigma Aldrich · Thermo Fisher Scientific · Trilink Biotechnologies For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
×
×
  • Create New...